New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
09:13 EDTLGND, GSKGlaxoSmithKline says FDA approves new indication for Promacta
GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration has approved Promacta for the treatment of thrombocytopenia, or low blood platelet counts, in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. There are limitations to the use of PROMACTA in patients suffering from chronic hepatitis C-associated thrombocytopenia, the company noted.
News For GSK;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
14:17 EDTGSKGlaxoSmithKline looking for buyers for Nicotinell business, AFR reports
GlaxoSmithKline is looking for a buyer for its Australian nicotine chewing gum business Nicotinell, according to the Australian Financial Review. Reference Link
10:01 EDTLGNDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Bacterin (BONE) initiated with a Buy at H.C. Wainwright... Cognizant (CTSH) initiated with a Buy at Argus... Comerica (CMA) initiated with a Neutral at UBS... Delphi Automotive (DLPH) initiated with a Neutral at Northcoast... Dunkin' Brands (DNKN) initiated with a Neutral at UBS... Easterly Government Properties (DEA) initiated with an Outperform at RBC Capital... Fifth Third (FITB) initiated with a Buy at UBS... Hilton (HLT) initiated with an Outperform at RBC Capital... KeyCorp (KEY) initiated with a Neutral at UBS... Ligand (LGND) initiated with a Buy at CRT Capital... M&T Bank (MTB) initiated with a Neutral at UBS... MPLX (MPLX) initiated with a Hold at Evercore ISI... Marriott (MAR) initiated with an Outperform at RBC Capital... Nexvet Biopharma (NVET) initiated with an Outperform at JMP Securities... Regions Financial (RF) initiated with a Neutral at UBS... Shell Midstream (SHLX) initiated with a Buy at Evercore ISI... Starwood (HOT) initiated with a Sector Perform at RBC Capital... Sunoco Logistics (SXL) initiated with a Hold at Evercore ISI... Syneron Medical (ELOS) initiated with a Buy at Brean Capital... Tesoro Logistics (TLLP) initiated with a Buy at Evercore ISI... Valero Energy Partners (VLP) initiated with a Buy at Evercore ISI... Vista Outdoor (VSTO) initiated with a Buy at CRT Capital... Zions Bancorp (ZION) initiated with a Sell at UBS.
08:23 EDTLGNDLigand initiated with a Buy at CRT Capital
Target $102.
March 2, 2015
09:19 EDTLGNDLigand data should establish superiority of Kyprolis, says Roth Capital
Subscribe for More Information
07:04 EDTGSKIsis Pharmaceuticals earns $15M from GlaxoSmithKline for advancing ISIS-TTR Rx
Isis Pharmaceuticals (ISIS) announced that it has earned a $15M milestone payment from GSK (GSK) related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug Isis is developing with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
February 25, 2015
12:13 EDTGSKGlaxoSmithKline sees Novartis transaction closing next week
Subscribe for More Information
11:24 EDTGSKGlaxoSmithKline announces return of alli to retail stores
Subscribe for More Information
February 23, 2015
13:33 EDTGSKRBS could name Howard Davies as chairman this week, FT reports
Royal Bank of Scotland (RBS) could name Howard Davies as its chairman as early as Thursday, when the bank reports its full-year results, the Financial Times reports. Davies is currently chairman of insurance business Phoenix Group and chairs Morgan Stanley's (MS) risk committee. Current RBS Chairman Philip Hampton is set to become GlaxoSmithKline's (GSK) chairman as early as this summer. Reference Link
11:17 EDTGSKFTC puts conditions on Novartis's proposed acquisition of GSK oncology drugs
According to the FTC, Global pharmaceutical company Novartis (NVS) has agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma (ARRY) to settle charges that Novartis’s $16B acquisition of GlaxoSmithKline’s (GSK) portfolio of cancer-treatment drugs would likely be anticompetitive...If the acquisition goes forward as proposed, Novartis would likely delay or terminate development of both its BRAF and MEK inhibitors, as well as the combination product. For that reason, Novartis’s acquisition of GSK’s portfolio of cancer-treatment drugs would likely cause significant competitive harm in the U.S. markets for both the BRAF and MEK inhibitors, ultimately raising prices for consumers and depriving them of potentially superior products. Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF and MEK inhibitor markets is not reduced. Reference Link
February 20, 2015
07:23 EDTGSKAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTGSKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use